Prensa
Noticias que puede verificar contra la fuente
La página de prensa de Naprod publica únicamente historias que pueden verificarse de forma independiente: un registro propio de un regulador, una publicación especializada identificada, o un anuncio corporativo con fecha. Nada aquí es un comunicado de prensa disfrazado de noticia.
4 historias registradas desde enero de 2026, incluido un hito regulatorio verificado por terceros: la renovación GMP de ANVISA de enero de 2026, informada por Pharma India Magazine.
Featured
ANVISA Renews GMP Certification for Naprod's Tarapur Sterile-Oncology Facility
Brazil's national health regulatory authority renewed Good Manufacturing Practice certification for Naprod's Tarapur plant in January 2026, keeping the sterile oncology injectables facility qualified to supply the Brazilian and wider Mercosur market.
Source: Pharma India Magazine and Medical Dialogues
Read the full story →Dated trail
Every other entry, dated and sourced
Company announcements are labeled as such and are not presented as independently verified unless they carry a named third-party source.
-
Naprod's Tarapur Register: 15 Manufacturing Accreditations Now Confirmed From Certificates on File
Following the January 2026 ANVISA renewal, Naprod's accreditation register now shows 15 of its 21 international certifications confirmed from the issued certificate held on file, with 6 more being digitized for publication.
Naprod Life Sciences (company announcement) -
Naprod to Showcase Oncology and Lyophilized Injectables at CPHI South East Asia 2026
Naprod Life Sciences will exhibit its oncology, injectable, and lyophilized formulation capabilities at CPHI South East Asia 2026 in Bangkok (Booth B31, 8–10 July 2026), inviting distributors and partners to discuss supply and partnership opportunities.
Naprod Life Sciences (LinkedIn) -
Naprod Appoints Smita Kadam as DGM, International Business
Naprod Life Sciences announced the appointment of Smita Kadam as Deputy General Manager, International Business, bringing 15 years of international business-development experience to strengthen the company's expansion across Latin America.
Naprod Life Sciences (LinkedIn) -
Naprod Reaffirms Oncology Supply Continuity Amid Platinum Raw-Material Constraints
Naprod Life Sciences stated its commitment to uninterrupted supply of platinum-based oncology injectables, including Cisplatin and Carboplatin, as industry-wide raw-material constraints affect availability, focusing on supply continuity for healthcare institutions.
Naprod Life Sciences (LinkedIn) -
Naprod Joins Pharma Eurasia 2026 in Tashkent to Expand Across CIS Markets
Naprod Life Sciences exhibited at Pharma Eurasia 2026 at Tashkent Pharma Park, Uzbekistan (Stall D15, 20–22 May 2026), connecting with partners across the Eurasian pharmaceutical market.
Naprod Life Sciences (LinkedIn) -
Naprod Details Oncology Injectable Manufacturing Capacity at Tarapur
Company update outlining current lyophilized and liquid oncology injectable capacity at the Tarapur site, alongside the facility's broader dosage-form output.
Naprod Life Sciences (company announcement)
Compromiso de actualidad
Una página de prensa que se verifica, no solo se publica
Esta sección de noticias estuvo inactiva desde 2019 en el sitio anterior. En adelante, cada entrada llevará una fecha de publicación, una línea de fuente y un indicador verificado. Los elementos reportados por terceros se marcan como verificados solo una vez comprobados frente al medio o registro regulatorio identificado; los anuncios de origen corporativo se marcan como tales y nunca se mezclan con cobertura independiente. No se publican aquí comunicados de prensa, entradas de blog, afirmaciones de premios ni nombres de programas de calidad, a menos que puedan rastrearse hasta una fuente identificada y verificable.
Pending approval Historical news content from before this rebuild (pre-2026) was not recoverable from available source material and is not represented here.
Para prensa y socios
Kit de prensa y contacto de prensa
Se está preparando un kit de prensa descargable (perfil corporativo, ficha técnica de la planta de Tarapur y activos de logotipo aprobados). Las consultas de prensa y de asuntos regulatorios pueden dirigirse al equipo de Calidad y Asuntos Regulatorios de Naprod; se publicará aquí un contacto de prensa identificado una vez que sea confirmado por la compañía.
Pending approval Media kit assets and a named press contact are PENDING APPROVAL; this section will link directly to the kit and list a contact once the company confirms them.